Two host factors regulate persistence of H7a-specific T cells injected in tumor-bearing mice

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Meunier, Marie Christine ^a,b,c   Baron, Chantal ^a,b,c   Perreault, Claude ^a,b,c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; THYMULIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER INFILTRATION; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL SPECIFICITY; CONTROLLED STUDY; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; RISK REDUCTION; SPLEEN; TARGET CELL; THYMUS; ANIMAL; C57BL MOUSE; EXPERIMENTAL NEOPLASM; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MOUSE STRAIN; T LYMPHOCYTE; TRANSPLANTATION;

MUS;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; THYMIC FACTOR, CIRCULATING;

EID: 58149469941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004116     Document Type: Article

References (53)

1. Bleakley M, Riddell SR (2004) Molecules and mechanisms of the graft-versusleukaemia effect. Nat Rev Cancer 4: 371-380.
2. Perreault C, Brochu S (2002) Adoptive cancer immunotherapy: discovering the best targets. J Mol Med 80: 212-218.
3. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411: 385-389.
4. Truitt RL (2004) The Mortimer M. Bortin Lecture: to destroy by the reaction of immunity: the search for separation of graft-versus-leukemia and graft-versushost. Biol Blood Marrow Transplant 10: 505-523.
5. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, et al. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6: 1018-1023.
6. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, et al. (2001) Adoptive transfer of T lymphocytes targeted to a single immunodominant minor histocompatibility antigen eradicates leukemia cells without causing graftversus-host disease. Nat Med 7: 789-794.
7. Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, et al. (2005) T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 11: 1222-1229.
8. Korngold R, Leighton C, Mobraaten LE, Berger MA (1997) Inter-strain graft vs. - host disease T-cell responses to immunodominant minor histocompatibility antigens. Biol Blood Marrow Transplant 3: 57-64.
9. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, et al. (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
10. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.
11. Yu P, Rowley DA, Fu YX, Schreiber H (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18: 226-231.
12. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24: 175-208.
13. Dulude G, Roy DC, Perreault C (1999) The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med 189: 1329-1342.
14. Meunier MC, Roy-Proulx G, Labrecque N, Perreault C (2003) Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy. Blood 101: 766-770.
15. Baron C, Meunier MC, Caron E, Côté C, Cameron MJ, et al. (2006) Asynchronous differentiation of CD8 T cells that recognize dominant and cryptic antigens. J Immunol 177: 8466-8475.
16. Blais ME, Gérard G, Martinic MM, Roy-Proulx G, Zinkernagel RM, et al. (2004) Do thymically and strictly extrathymically developing T cells generate similar immune responses? Blood 103: 3102-3110.
17. Wells AD, Gudmundsdottir H, Turka LA (1997) Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 100: 3173-3183.
18. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171: 131-137.
19. Gudmundsdottir H, Wells AD, Turka LA (1999) Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol 162: 5212-5223.
20. + T-cell responses. Curr Opin Immunol 16: 259-263.
21. + T-cell response. Nat Rev Immunol 4: 595-602.
22. Pion S, Fontaine P, Desaulniers M, Jutras J, Filep JG, et al. (1997) On the mechanisms of immunodominance in cytotoxic T lymphocyte responses to minor histocompatibility antigens. Eur J Immunol 27: 421-430.
23. Roy-Proulx G, Meunier MC, Lanteigne AM, Brochu S, Perreault C (2001) Immunodomination results from functional differences between competing CTL. Eur J Immunol 31: 2284-2292.
24. Roy-Proulx G, Baron C, Perreault C (2005) CD8 T-cell ability to exert immunodomination correlates with T-cell receptor:epitope association rate. Biol Blood Marrow Transplant 11: 260-271.
25. van Elsas A, Sutmuller RPM, Hurwitz AA, Ziskin J, Villasenor J, et al. (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194: 481-490.
26. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273.
27. Di Rosa F, Pabst R (2005) The bone marrow: a nest for migratory memory T cells. Trends Immunol 26: 360-366.
28. dom1) encoded by the classical H7 minor histocompatibility locus. J Immunol 162: 4502-4510.
29. dom1 minor histocompatibility antigen is encoded by a mouse homolog of the yeast STT3 gene. Immunogenetics 54: 562-569.
30. + T cells. Immunity 22: 259-270.
31. + T cells expressing the same or different T cell receptors. Proc Natl Acad Sci U S A 101: 3041-3046.
32. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD (2003) Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3: 431-437.
33. Nijmeijer BA, van Schie ML, Verzaal P, Willemze R, Falkenburg JH (2005) Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia. Exp Hematol 33: 1172-1181.
34. Riddell SR, Bleakley M, Nishida T, Berger C, Warren EH (2006) Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant 12: 9-12.
35. Mutis T, Gillespie G, Schrama E, Falkenburg JHF, Moss P, et al. (1999) Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 5: 839-842.
36. Choi EY, Christianson GJ, Yoshimura Y, Jung N, Sproule TJ, et al. (2002) Realtime T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood 100: 4259-4264.
37. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99: 16168-16173.
38. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, et al. (2004) Vaccinationinduced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 64: 1509-1514.
39. Obhrai JS, Oberbarnscheidt MH, Hand TW, Diggs L, Chalasani G, et al. (2006) Effector T cell differentiation and memory T cell maintenance outside secondary lymphoid organs. J Immunol 176: 4051-4058.
40. Oosten LE, Blokland E, Van Halteren AG, Curtsinger J, Mescher MF, et al. (2004) Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 104: 224-226.
41. Heemskerk MHM, Hoogeboom M, Hagedoorn R, Kester MGD, Willemze R, et al. (2004) Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 199: 885-894.
42. + T cells against human leukemia-associated minor histocompatibility antigens. Cancer Res 66: 5436-5442.
43. + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 96: 8639-8644.
44. Uhr JW, Scheuermann RH, Street NE, Vitetta ES (1997) Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 3: 505-509.
45. Zinkernagel RM, Planz O, Ehl S, Battegay M, Odermatt B, et al. (1999) General and specific immunosuppression caused by antiviral T-cell responses. Immunol Rev 168: 305-315.
46. Hambach L, Goulmy E (2005) Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 17: 202-210.
47. Rijke BD, Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, et al. (2005) A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 115: 3506-3516.
48. Brickner AG, Evans AM, Mito JK, Xuereb SM, Feng X, et al. (2006) The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 107: 3779-3786.
49. Klein CA, Wilke M, Pool J, Vermeulen C, Blokland E, et al. (2002) The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med 196: 359-368.
50. Spierings E, Wieles B, Goulmy E (2004) Minor histocompatibility antigens - big in tumour therapy. Trends Immunol 25: 56-60.
51. Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, et al. (2005) Agedependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 115: 930-939.
52. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, et al. (1983) Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 98: 461-466.
53. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, et al. (2002) Chronic graftversus-host disease in children: incidence, risk factors, and impact on outcome. Blood 100: 1192-1200.